Merck Receives 2014 ENERGY STAR Sustained Excellence Award From US Environmental Protection Agency
![](/46/pdcnewsitem/03/32/28/DWYtvqm19k8cL4N.jpg)
Merck (MSD) has received an ENERGY STAR 2014 Partner of the Year — Sustained Excellence Award from the US Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 9 consecutive years, twice as Partner of the Year and now a seventh time for Sustained Excellence.
“Managing energy well is consistent with Merck's philosophy of being a responsible company,” said Rodney Freeman, vice president, Global Facilities Management, Merck. “We are using greener sources of energy and reducing greenhouse gas emissions. Our partnership with ENERGY STAR helps us focus on our main goal of reducing energy consumption. We believe the greenest kilowatt is the one not used.”
The award recognizes four Merck manufacturing sites that have achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Arecibo, Puerto Rico, Cleveland, Tenn., Las Piedras, Puerto Rico; and Elkhorn, Neb.
Also achieving certification this year were two buildings at Merck's corporate headquarters in Whitehouse Station, NJ, Merck’s office buildings in Upper Gwynedd, Pa., West Point, Pa., and for the first time, Cokesbury, NJ In addition, four sites in Europe were recognized for meeting the ENERGY STAR Challenge for Industry by reducing their energy intensity by 10%over a 5-year period. The sites recognized are Heist, Belgium; Swords, Ireland; Cramlington, UK; and Mirabel, France.
“Merck has earned EPA’s highest ENERGY STAR award — the 2014 Partner of the Year — Sustained Excellence Award — because of its unwavering commitment to helping consumers become increasingly more energy efficient,” said EPA Deputy Administrator Bob Perciasepe.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance